Pfizer uses COVID profits to fuel new growth

Article Excerpt

Pfizer used the huge profits from its COVID-19 products to buy makers of other promising drugs, particularly cancer treatments. These new drugs should drive the company’s long-term growth, and let it keep raising your dividend. PFIZER INC. $29 is your #1 Income Buy for 2024. The company (New York symbol PFE; Income Portfolio, Manufacturing & Industry sector; Shares outstanding: 5.7 billion; Market cap: $165.3 billion; Price-to-sales ratio: 3.0; Dividend yield: 5.8%; TSINetwork Rating: Above Average; www.pfizer.com) began operating in 1849 and is now one of the world’s largest makers of prescription drugs. Its top-selling brands include Eliquis (stroke), Ibrance (breast cancer) and Prevnar (pneumonia). The company’s revenue fell 19.0%, from $51.75 billion in 2019 to $41.91 billion in 2020. That’s because Pfizer merged its Upjohn business (generic drugs) with Netherlands-based Mylan N.V. and spun off that firm (called Viatris) as a separate firm. Pfizer investors received 0.124079 of a Viatris share for each Pfizer share they held. However, revenue jumped to $81.29 billion in 2021 and…